Delivering the Next Wave of Gene Therapies to the CNS
Streamlining CNS Drug Delivery Devices for Improved Brain Biodistribution; Discovering Novel Vectors for CNS Specificity & Tropism; & Optimizing Gene Therapy Strategy for Paediatric & Adult Neurological Disorders
This December, the 4th Annual Gene Therapy for Neurological Disorders meeting is returning to Boston to welcome discovery, preclinical, translational and clinical industry scientists to share, learn and network for the shared goal of successfully and safely delivering gene therapies to the CNS.
Join the expanding audience of gene therapy experts seeking to overcome the translational hurdles of developing gene therapies for CNS targets, from discovery, preclinical, translational, clinical, and commercial departments at the likes of Capsigen, AviadoBio, AskBio,Novartis, Prevail Therapeutics,Passage Bio,Voyager Therapeutics,UniQure, Eli Lilly and more.
A Snapshot Of Previous Speakers
Ronald Crystal
Founder & Chief Scientific Advisor (President & Chairman, Department of Genetic Medicine)
Lexeo Therapeutics (Weill Cornell Medical College)
(V)
Steven Gray
Associate Professor; Chief Scientific Adviser
University of Texas Southwestern Medical Center; Taysha Gene Therapies
(V)
Proud to Partner With
Other Events in the Gene Therapy Series
